Cargando…

Factors affecting patient-acceptable symptom states and treatment decision in familial Mediterranean fever

BACKGROUND/AIM: Familial Mediterranean fever [FMF] is the most common autoinflammatory disease characterized by inflammatory attacks of fever and polyserositis. Patients’ quality of life is significantly affected due to recurrent excruciating pain attacks and complications. This study is performed t...

Descripción completa

Detalles Bibliográficos
Autores principales: YILDIRIM, Derya, VASİ, İbrahim, TAHTA, Erdi, KARDAŞ, Rıza Can, ÖZKIZILTAŞ, Burcugül, KÜÇÜK, Hamit, ÖZTÜRK, Mehmet Akif, HAZNEDAROĞLU, Şeminur, GÖKER, Berna, TUFAN, Abdurrahman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Scientific and Technological Research Council of Turkey (TUBITAK) 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390155/
https://www.ncbi.nlm.nih.gov/pubmed/36945975
http://dx.doi.org/10.55730/1300-0144.5547
_version_ 1785082417998987264
author YILDIRIM, Derya
VASİ, İbrahim
TAHTA, Erdi
KARDAŞ, Rıza Can
ÖZKIZILTAŞ, Burcugül
KÜÇÜK, Hamit
ÖZTÜRK, Mehmet Akif
HAZNEDAROĞLU, Şeminur
GÖKER, Berna
TUFAN, Abdurrahman
author_facet YILDIRIM, Derya
VASİ, İbrahim
TAHTA, Erdi
KARDAŞ, Rıza Can
ÖZKIZILTAŞ, Burcugül
KÜÇÜK, Hamit
ÖZTÜRK, Mehmet Akif
HAZNEDAROĞLU, Şeminur
GÖKER, Berna
TUFAN, Abdurrahman
author_sort YILDIRIM, Derya
collection PubMed
description BACKGROUND/AIM: Familial Mediterranean fever [FMF] is the most common autoinflammatory disease characterized by inflammatory attacks of fever and polyserositis. Patients’ quality of life is significantly affected due to recurrent excruciating pain attacks and complications. This study is performed to evaluate the parameters most affecting patients’ satisfaction from treatment. MATERIALS AND METHODS: Three hundred and forty-six consecutive patients diagnosed with FMF were enrolled in this study. Current treatment, acute phase proteins, number, type, and severity of predominant attacks, absenteeism from work/school in the last three months were recorded, and the participants were asked whether they needed additional treatment to evaluate Patient Acceptable Symptom State (PASS) status. RESULTS: Mean age of the overall group was 38.2 ± 11.7 years (62.4% female, 37.6% male). Two hundred and twenty-seven patients were treated with colchicine, 97 patients with colchicine plus Interleukin-1 (IL-1) antagonist, and 22 only with IL-1 antagonist (67.1%, 26.3%, 6.64% in order). Of the overall group, 33.8% (n = 117) believed to need additional treatment options. Additional treatment need of patients was significantly affected by work impairment due to attacks, absent days from work, disease activity, the discomfort of patients during attacks, the number of attacks, and treatment options; but not by the level of acute-phase proteins between attacks. CONCLUSION: PASS score is significantly related to clinical parameters and quality of life. Patients’ PASS scores and treatment choices are notably affected by the severity and frequency of attacks and absenteeism from work/school. Clinical activity and quality of life should be evaluated at every visit to provide patients’ satisfaction with treatment.
format Online
Article
Text
id pubmed-10390155
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Scientific and Technological Research Council of Turkey (TUBITAK)
record_format MEDLINE/PubMed
spelling pubmed-103901552023-08-01 Factors affecting patient-acceptable symptom states and treatment decision in familial Mediterranean fever YILDIRIM, Derya VASİ, İbrahim TAHTA, Erdi KARDAŞ, Rıza Can ÖZKIZILTAŞ, Burcugül KÜÇÜK, Hamit ÖZTÜRK, Mehmet Akif HAZNEDAROĞLU, Şeminur GÖKER, Berna TUFAN, Abdurrahman Turk J Med Sci Research Article BACKGROUND/AIM: Familial Mediterranean fever [FMF] is the most common autoinflammatory disease characterized by inflammatory attacks of fever and polyserositis. Patients’ quality of life is significantly affected due to recurrent excruciating pain attacks and complications. This study is performed to evaluate the parameters most affecting patients’ satisfaction from treatment. MATERIALS AND METHODS: Three hundred and forty-six consecutive patients diagnosed with FMF were enrolled in this study. Current treatment, acute phase proteins, number, type, and severity of predominant attacks, absenteeism from work/school in the last three months were recorded, and the participants were asked whether they needed additional treatment to evaluate Patient Acceptable Symptom State (PASS) status. RESULTS: Mean age of the overall group was 38.2 ± 11.7 years (62.4% female, 37.6% male). Two hundred and twenty-seven patients were treated with colchicine, 97 patients with colchicine plus Interleukin-1 (IL-1) antagonist, and 22 only with IL-1 antagonist (67.1%, 26.3%, 6.64% in order). Of the overall group, 33.8% (n = 117) believed to need additional treatment options. Additional treatment need of patients was significantly affected by work impairment due to attacks, absent days from work, disease activity, the discomfort of patients during attacks, the number of attacks, and treatment options; but not by the level of acute-phase proteins between attacks. CONCLUSION: PASS score is significantly related to clinical parameters and quality of life. Patients’ PASS scores and treatment choices are notably affected by the severity and frequency of attacks and absenteeism from work/school. Clinical activity and quality of life should be evaluated at every visit to provide patients’ satisfaction with treatment. Scientific and Technological Research Council of Turkey (TUBITAK) 2022-06-13 /pmc/articles/PMC10390155/ /pubmed/36945975 http://dx.doi.org/10.55730/1300-0144.5547 Text en © TÜBİTAK https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License.
spellingShingle Research Article
YILDIRIM, Derya
VASİ, İbrahim
TAHTA, Erdi
KARDAŞ, Rıza Can
ÖZKIZILTAŞ, Burcugül
KÜÇÜK, Hamit
ÖZTÜRK, Mehmet Akif
HAZNEDAROĞLU, Şeminur
GÖKER, Berna
TUFAN, Abdurrahman
Factors affecting patient-acceptable symptom states and treatment decision in familial Mediterranean fever
title Factors affecting patient-acceptable symptom states and treatment decision in familial Mediterranean fever
title_full Factors affecting patient-acceptable symptom states and treatment decision in familial Mediterranean fever
title_fullStr Factors affecting patient-acceptable symptom states and treatment decision in familial Mediterranean fever
title_full_unstemmed Factors affecting patient-acceptable symptom states and treatment decision in familial Mediterranean fever
title_short Factors affecting patient-acceptable symptom states and treatment decision in familial Mediterranean fever
title_sort factors affecting patient-acceptable symptom states and treatment decision in familial mediterranean fever
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390155/
https://www.ncbi.nlm.nih.gov/pubmed/36945975
http://dx.doi.org/10.55730/1300-0144.5547
work_keys_str_mv AT yildirimderya factorsaffectingpatientacceptablesymptomstatesandtreatmentdecisioninfamilialmediterraneanfever
AT vasiibrahim factorsaffectingpatientacceptablesymptomstatesandtreatmentdecisioninfamilialmediterraneanfever
AT tahtaerdi factorsaffectingpatientacceptablesymptomstatesandtreatmentdecisioninfamilialmediterraneanfever
AT kardasrızacan factorsaffectingpatientacceptablesymptomstatesandtreatmentdecisioninfamilialmediterraneanfever
AT ozkiziltasburcugul factorsaffectingpatientacceptablesymptomstatesandtreatmentdecisioninfamilialmediterraneanfever
AT kucukhamit factorsaffectingpatientacceptablesymptomstatesandtreatmentdecisioninfamilialmediterraneanfever
AT ozturkmehmetakif factorsaffectingpatientacceptablesymptomstatesandtreatmentdecisioninfamilialmediterraneanfever
AT haznedarogluseminur factorsaffectingpatientacceptablesymptomstatesandtreatmentdecisioninfamilialmediterraneanfever
AT gokerberna factorsaffectingpatientacceptablesymptomstatesandtreatmentdecisioninfamilialmediterraneanfever
AT tufanabdurrahman factorsaffectingpatientacceptablesymptomstatesandtreatmentdecisioninfamilialmediterraneanfever